-
04-222026
Forlong Biotechology to Present Clinical Data from the first-in-human study for FL115 (IL-15 superagonist) in US Patients with Advanced Solid tumors at 2026 ASCO Annual Meeting
-
04-162026
Forlong Biotechology Announced CMC Readiness to Initiate GMP Batch Production to Support upcoming Pivotal Clinical Trial for FL115 (IL-15 Superagonist) in Nonmuscle Invasive Bladder Cancer (NMIBC)
-
03-172026
PR-Forlong to present IL-15 and IL-18 data at AACR
-
01-072026
Forlong Biotechology Announced Activation of Phase Ib/II Study of FL115 （IL-15 Superagonist）in combination with anti-PD-1 Antibody for Patients with Advanced Solid Tumor and Acceptance of IND for FL115 Subcutaneous Injection by NMPA
-
10-312025
Forlong Dosed First Patient in Phase 2 Clinical Trial of FL115, a novel interleukin-15 (IL-15) superagonist, for nonmuscle invasive bladder cancer (NMIBC)
-
10-312025
Forlong Biotechology to Present Clinical Data from FL115, a novel interleukin-15 (IL-15) superagonist, in Late-breaking Session at 40th SITC Annual Meeting
-
10-222025
Forlong Biotechology Announces Collaboration Agreement with Henlius to Develop Innovative Cancer Immunotherapy with an Engineered Cytokine
-
10-152025
Forlong Biotechology Announces Receiving Milestone Payment as Partner Submits IND for A Protein Therapy using its Proprietary Fbody® Long-acting Technology
-
07-102025
Forlong Biotech Announces CDE Clearance for Phase Ib/II IND of FL115 (IV) Plus PD-1(Sintilimab) in Patients with Advanced Solid Tumors
-
02-152025
Forlong Biotech Announces Dosing First Patient in Phase Ib Trial of FL115 (Intravesical) plus BCG for NMIBC
-
12-262024
Forlong and Innovent Enter into Clinical Trial Collaboration to Investigate the Combination of FL115 and Sintilimab in Advanced Solid Tumors
-
08-262024
Forlong Biotech Announces Dosing First Patient in Phase I/II Trial of FL115 (Intravesical Instillation) in patients with NMIBC
苏公网安备32050502011888号